Lavelle Ellis, MD
Gastroenterology · Salina, KSNPI 1265497002
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 34.6% of the total. Reporting peaked in 2022 at $688 and has fallen 58.2% since, to $287 in 2024.
Across 194 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$417
- Takeda Pharmaceuticals U.S.A., Inc.$306
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$283
- Gilead$184
- Merck$172
- plus $643 from 16 others
What the payments were for
- Food & beverage$2,97597%
- Education$903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,060 |
| Johnson & Johnson | 28 | $417 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $306 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $283 |
| Gilead | 8 | $184 |
| Merck | 12 | $172 |
| Intercept Pharmaceuticals, Inc. | 9 | $137 |
| Sanofi | 2 | $112 |
| Pfizer | 5 | $82 |
| Lilly USA, LLC | 2 | $60 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Bristol Myers Squibb | 2 | $28 |
| Boehringer Ingelheim | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Sandoz | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| Conmed Corporation | 1 | $17 |
| Celltrion USA Inc. | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $11 |
How this compares
$3,065 in reported general payments places this provider in the 65th percentile of 98 gastroenterology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 44 | $1,180,070 |
| OcalivaObeticholic Acid | 49 | $462,241 |
| Humira(Cf) PenAdalimumab | 20 | $140,693 |
| CreonLipase/Protease/Amylase | 39 | $117,991 |
| ZenpepLipase/Protease/Amylase | 17 | $36,112 |
| XifaxanRifaximin | 16 | $30,865 |
| Mesalamine | 56 | $29,680 |
| ViberziEluxadoline | 11 | $19,472 |
| LinzessLinaclotide | 33 | $18,914 |
| TrulancePlecanatide | 21 | $14,119 |
| MovantikNaloxegol Oxalate | 19 | $9,251 |
| Colestipol Hcl | 184 | $8,279 |
| Balsalazide Disodium | 51 | $7,249 |
| Ursodiol | 56 | $7,115 |
| Mesalamine DrMesalamine | 15 | $6,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $417 | $1,180,07044 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $137 | $462,24149 claims |
| AbbVieCreon, Viberzi, Linzess | $1,060 | $156,37783 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Apriso | $283 | $50,66748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 98 gastroenterology providers in Kansas.
Other gastroenterology in Salina
- Jesica BrownSalina$4K
- Paul JohnsonSalina$3K
- Luke JohnsonSalina$3K
- Phani Ashok AttaluriOlathe$957K
- Ryan TaylorKansas City$241K
- Winston DunnKansas City$169K
- Francis DaileyLeawood$82K
- Rashmi TadiparthiKansas City$60K
- Prateek SharmaKansas City$47K
- Erica DaileyOverland Park$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.